PROTAC SMARCA2 degrader-16 is a small molecule designed as a targeted protein degradation agent, specifically aimed at the SMARCA2 protein, which is involved in chromatin remodeling and has implications in various cancers. As a member of the PROTAC (Proteolysis Targeting Chimera) class, it functions by harnessing the cellular ubiquitin-proteasome system to selectively degrade the target protein. This compound typically features a bifunctional structure, comprising a ligand that binds to SMARCA2 and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. The design of PROTACs like SMARCA2 degrader-16 aims to enhance the specificity and efficacy of therapeutic interventions by reducing off-target effects commonly associated with traditional small molecule inhibitors. Additionally, the compound's pharmacokinetic properties, solubility, and stability are crucial for its potential therapeutic application, although specific details would require empirical data. Overall, PROTAC SMARCA2 degrader-16 represents a novel approach in targeted cancer therapy, emphasizing the importance of protein homeostasis in disease management.

PROTAC SMARCA2 degrader-16

2568276-37-7: PROTAC SMARCA2 degrader-16 is a small molecule designed as a targeted protein degradation agent, specifically aimed at the SMARCA2 protein, which is involved in chromatin remodeling and has implications in various cancers. As a member of the PROTAC (Proteolysis Targeting Chimera) class, it functions by harnessing the cellular ubiquitin-proteasome system to selectively degrade the target protein. This compound typically features a bifunctional structure, comprising a ligand that binds to SMARCA2 and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. The design of PROTACs like SMARCA2 degrader-16 aims to enhance the specificity and efficacy of therapeutic interventions by reducing off-target effects commonly associated with traditional small molecule inhibitors. Additionally, the compound's pharmacokinetic properties, solubility, and stability are crucial for its potential therapeutic application, although specific details would require empirical data. Overall, PROTAC SMARCA2 degrader-16 represents a novel approach in targeted cancer therapy, emphasizing the importance of protein homeostasis in disease management.

<p>PROTAC SMARCA2 degrader-16 (compound I-278) is a PROTAC targeting SMARCA2. It demonstrates degradation of the SMARCA2 protein with a DC50&lt;100 nM in A549 cells, achieving a maximal degradation rate (Dmax%) of over 90% after 24 hours of treatment.</p>

CAS 2568276-37-7

PROTAC SMARCA2 degrader-16

PROTAC SMARCA2 degrader-16

Ref: TM-T200618